Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Blood pressure
研究概览
简要总结
The aim of the present study is to compare the effects of different types of antihypertensive drugs (angiotensin II receptor blockers and long-acting calcium channel blockers) in patients with hypertension and obstructive sleep apnea who are not controlled well with their hypertension after continuous positive airway pressure therapy.
详细描述
Obstructive sleep apnea (OSA) and hypertension have a significant interrelationship, and both disorders are well known risk factors for cardiovascular diseases (CVD). Treating them appropriately may improve the prognosis of the patients. Presently, continuous positive airway pressure (CPAP) therapy is the first-line therapy for OSA, and angiotensin II receptor blockers and long-acting calcium channel blockers for hypertension in Japan. Therefore, in the present study, we wanted to compare the effects of these different types of antihypertensive drugs on the control of blood pressure in patients with OSA whose hypertension is not controlled well after CPAP therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Apnea and hypopnea index of more than 20 /hr, and treated with CPAP
- •Uncontrolled hypertension (defined as systolic blood pressure of more than 130 mmHg or diastolic blood pressure of more than 80 mmHg
排除标准
- •Cerebrovascular diseases, myocardial infarction, angina pectoris or heart failure within 6 months
- •Uncontrolled arrhythmia
- •Severe hepatic or renal disorders
- •Having poor prognosis disorders such as malignant disorders
研究组 & 干预措施
ARB plus increased ARB
angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
干预措施: Olmesartan and Azelnidipine (Drug)
ARB plus CCB
angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
干预措施: Olmesartan and Azelnidipine (Drug)
CCB plus ARB
calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
干预措施: Olmesartan and Azelnidipine (Drug)
结局指标
主要结局
Blood pressure
时间窗: Six months
次要结局
- Health-related quality of life(Six months)
- Oxygen desaturation index(Six months)
- Pulse rate(Six months)
- Endothelial dysfunction(Six months)
- Sleep quality and sleepiness(Six months)
研究者
Toru Oga
Respiratory Care and Sleep Control Medicine, Kyoto University, Graduate School of Medicine
Kyoto University, Graduate School of Medicine